Navigation Links
Shire Announces Support for Inflammatory Bowel Disease (IBD) Fellowships at Leading Medical Institutions Nationwide
Date:8/31/2010

PHILADELPHIA, Aug. 31 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced its support for inflammatory bowel disease (IBD) fellowships at leading medical institutions across the country.  The six fellowships will begin in 2011 and will provide a year of training in the management of IBD to physicians who recently completed a fellowship in gastroenterology.

"We are proud to support the education of future medical professionals," said Roger Adsett, senior vice president of Shire's gastroenterology business unit.  "As a company committed to advancing gastroenterology, we hope the individuals who complete the Shire-supported fellowships will provide important contributions to bettering patient care."

Institutions receiving support from Shire in the form of charitable contributions include: Cedars-Sinai Medical Center (Los Angeles), Cleveland Clinic, Mayo Clinic (Rochester, Minn.), Mount Sinai Medical Center (New York), University of California, San Francisco, and University of Chicago Medical Center. Shire selected these Centers of Excellence based on the centers' existing fellowship programs.

"Thanks to Shire's generous support, we will be able to increase the number of practicing physicians dedicated to treating inflammatory bowel disease, for which there is a growing need," said Daniel Present, MD, clinical professor of medicine and gastroenterology, at New York's Mount Sinai School of Medicine.  "Fellowships are vital in generating valuable research and improving patient care."

The institutions selected the fellowship recipients in June for fellowships that will begin July 2011.  Medical students were selected for the fellowships by the individual medical institutions based on pre-existing criteria.

For further information
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pentasa(R) - Shire Receives Ruling From FDA on Citizens Petition
2. Shire Purchases Strategic Site in Massachusetts
3. Shire Receives LIALDA(R) Paragraph IV Notice Letter From Zydus Pharmaceuticals
4. Area Residents Can Give a Little, Help A Lot at Shires BIG GIVE
5. Shire Receives INTUNIV(TM) Paragraph IV Notice Letter From Anchen
6. Excellent Results in a Transformational Year for Shire; Core Product Sales up 25%
7. Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naive Patients With Type 1 Gaucher Disease
8. Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA)
9. Shire Expands its Award-Winning ADHD Support Resource, ADHDSupport.com, by Launching an ADHD Twitter(TM) Page
10. Shire and Teva Settle Litigation Concerning Supply of ADDERALL XR Authorized Generic
11. Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV(TM) (guanfacine) Extended-Release Tablets with Stimulants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014   Bluegrass ... focused on innovating lifesaving devices and methods for ... million in Series A financing, which was led ... from the deal will allow Bluegrass Vascular to ... Catheter System, enhance manufacturing capabilities, and proceed with ...
(Date:7/30/2014)... 30, 2014  PDL BioPharma, Inc. (PDL) (NASDAQ: ... participate in the Jefferies 2014 Boston Healthcare Summit next ... will occur on August 6, 2014 and will not ... PDL BioPharma manages a portfolio of patents and ... antibody humanization patents and license agreements with various biotechnology ...
(Date:7/30/2014)... , 30. Juli 2014 Die ... führender Anbieter im Bereich Atemtherapie- und Druckzonenprodukte, ... Landgerichts München in Deutschland anfechten werden. Dieses ... Masken ein Patent von ResMed verletze. Apex ... wichtigen Ländern gegen verschiedene Patente von ResMed ...
Breaking Medicine Technology:Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2PDL BioPharma to Participate in Jefferies 2014 Boston Healthcare Summit 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 3
... Near-Complete Mitigation of Choroidal,Neovascularization (CNV) in an AMD ... Lpath, Inc. ,the category leader in therapeutic agents ... standard animal,model of human age-related macular degeneration (AMD). ... meeting of the,Association of Research in Vision and ...
... of SEROQUEL XR--, WILMINGTON, Del., May 22, ... analyses from a large-scale,study that investigated the ... a once-daily medicine for the,treatment of schizophrenia ... annual meeting of the American Psychiatric Association,(APA). ...
Cached Medicine Technology:Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 2Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 3Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 4New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 2New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 3New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 4New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 5New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 6New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 7New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 8New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 9
(Date:7/30/2014)... (PRWEB) July 30, 2014 It is said ... proved this to be true as a product sponsor ... in Las Vegas this past June. , Lash Affair ... and overall success of the eyelash industry through collaboration so ... proud to have supported NEESA ’s event. Lash Affair’s ...
(Date:7/30/2014)... mutation linked to obesity respond differently to pictures of ... not have the genetic mutation, according to a new ... Clinical Endocrinology & Metabolism ( JCEM ). , ... results from a combination of eating too much, getting ... of appetizing foods that are high in calories can ...
(Date:7/30/2014)... Texas (PRWEB) July 30, 2014 The ... (2013-18)” provides an insight into the market dynamics and ... report covers the actual and forecasted market sizing of ... various factors fuelling the demand of the same. It ... segment and major players in the market. Further, the ...
(Date:7/30/2014)... July 30, 2014 Dialogic ... today announced that DollarPhone, the largest privately owned ... the Dialogic® ControlSwitch™ softswitch to offer ... number portability (LNP) to both its wholesale and ... ControlSwitch is able to power DollarPhone’s network infrastructure, ...
(Date:7/30/2014)... HealthDay Reporter , TUESDAY, July ... might set the stage for harmful health habits, including eating ... conducted from 1982 to 2012 also found a link between ... younger a woman was when she started her first diet, ... control behaviors -- like vomiting or laxative misuse," said study ...
Breaking Medicine News(10 mins):Health News:Lash Affair Launches a New Product as Sponsor of the First U.S. Lash Extension Competition 2Health News:Brain response to appetizing food cues varies among obese people 2Health News:Global Pulse Oximetry Market 2018 Opportunities and Trends Now Available at MarketReportsOnline.com 2Health News:Global Pulse Oximetry Market 2018 Opportunities and Trends Now Available at MarketReportsOnline.com 3Health News:DollarPhone Expands Prepaid and Wholesale Offerings With Enhanced Dialogic ControlSwitch 2Health News:DollarPhone Expands Prepaid and Wholesale Offerings With Enhanced Dialogic ControlSwitch 3Health News:Dieting at Young Age Often Backfires, Study Says 2Health News:Dieting at Young Age Often Backfires, Study Says 3
... analysis of records of pancreatic surgery during the last ... pancreatic cancer surgeon// Charles J. Yeo, M.D., Samuel D. ... College of Thomas Jefferson University and Thomas Jefferson University ... his colleagues have revealed that contrary to what many ...
... major intestinal surgery, including stomach reduction for obesity, may ... results of the study have been published in the ... findings on three patients with increasingly poor eyesight or ... the space of a year. None of the patients ...
... A number of Canadians are more obese ... smoking less, according to a new national health survey// . ... Canada, on Tuesday, revealed that there was an underestimation ... by approximately nine per cent. The survey also indicated ...
... that a man is very critical and is suspected to have ... in a Shenzhen hospital. It is very evident that the virus ... Health Protection said that the victim lives in Shenzhen and is ... residing in Shenzhen. He fell ill after he visited a wet ...
... Families who fear the transfer of genetic diseases to their progeny ... a major NHS bank of babies' stem cells//. ,Stem ... to treat diseases such as leukemia. However cord blood banking has ... public as well as clinicians, wherein blood is taken from the ...
... warn the number of New Zealanders who take party pills ... authorities argued taking// party pills escape people from taking drugs. ... used the pill atleast once – says researchers commissioned by ... physical and psychological parts such as sleeplessness, loss of appetite, ...
Cached Medicine News:Health News:Pancreatic Cancer Surgery Successful in 80-Year-Olds 2Health News:Pancreatic Cancer Surgery Successful in 80-Year-Olds 3Health News:Incidence Of Smoking Less, Obesity More, in Canada: StatsCan 2Health News:Bank of Stem Cells to Give Hope to Sick Children 2
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Nucleus manipulator used during phacoemulsification. Used to break-up the nuclues within the capsular bag during two-handed phaco techniques. Blunt round tip, angled 40 degrees, 11mm from tip. Tip an...
... effective upgrade path that allows users to ... modularity. The potential to combine two units ... a single stimulating coil. The ability to ... the power level of each Magstim 200 ...
... The Magstim Model 200 uses a ... otherwise inaccessible nerves. World market leader in ... developed by the University of Sheffield in ... cortical hemispheric and peripheral stimulation. Our best ...
Medicine Products: